In early 2022, the CF AMR Syndicate published our first-ever patient-focused therapeutic target product profile (TPP) guidance document for treating lung infections in CF. Building on this, the CF AMR Syndicate went on to announce their first funding call in March 2023, pledging £3M to support innovators and accelerate the development of novel antimicrobials to the clinic.
The collaborative funding programme has been shaped around the needs and priorities of people with CF highlighted in the TPP guidance document.
To understand more about the value of these TPPs, their application, and how you might get involved, read more here.
